Anti-tumor necrosis factor treatment in cherubism - Clinical, radiological and histological findings in two children

Bone

Volumn 52, Issue 1, 2013, Pages 347-353

  Hero, M ^a   Suomalainen, A ^b   Hagstrom J ^c,d   Stoor, P ^b   Kontio, R ^b   Alapulli, H ^b   Arte, S ^b   Toiviainen Salo, S ^e   Lahdenne, P ^a   Makitie O ^a,f  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f FOLKHÄLSAN RESEARCH CENTER   (Finland)

Author keywords

Adalimumab; Cherubism; SH3 binding protein 2; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ADENINE; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CYTOSINE; HISTIDINE; LEUCINE; PROLINE; THYMINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BONE BIOPSY; CASE REPORT; CELL COUNT; CHILD; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DENTAL SURGERY; DISEASE COURSE; DISEASE MARKER; DRUG ACTIVITY; DRUG FEVER; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACE DEFORMITY; FEMALE; FIBROUS DYSPLASIA; FOLLOW UP; GENE; GENE MUTATION; GIANT CELL GRANULOMA; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INJECTION SITE PAIN; JAW MALFORMATION; JAW RADIOGRAPHY; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; OSSIFICATION; OSTEOLYSIS; PHENOTYPE; PNEUMONIA; PRESCHOOL CHILD; REMISSION; SH3BP2 GENE; SIDE EFFECT; TOOTH MALFORMATION; UPPER RESPIRATORY TRACT INFECTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CHERUBISM; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868566988     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.003     Document Type: Article

References (21)

1. Von Wowern N. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 90:765-772.
2. Battaglia A., Merati A., Magit A. Cherubism and upper airway obstruction. Otolaryngol Head Neck Surg 2000, 122:573-574.
3. Carroll A.L., Sullivan T.J. Orbital involvement in cherubism. Clin Experiment Ophthalmol 2001, 29:38-40.
4. Mortellaro C., Bello L., Lucchina A.G., Pucci A. Diagnosis and treatment of familial cherubism characterized by early onset and rapid development. J Craniofac Surg 2009, 20:116-120.
5. Barnes L., Eveson J.W., Reichardt P., Sidrasky D. Pathology & genetics, head and neck tumours 2005, WHO, IARC Press, Lyon.
6. Mangion J., Rahman N., Edkins S., Barfoot R., Nguyen T., Sigurdsson A., et al. The gene for cherubism maps to chromosome 4p16.3. Am J Hum Genet 1999, 65:151-157.
7. Ueki Y., Tiziani V., Santanna C., Fukai N., Maulik C., Garfinkle J., et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001, 28:125-126.
8. Levaot N., Voytyuk O., Dimitriou I., Sircoulomb F., Chandrakumar A., Deckert M., et al. Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011, 147:1324-1339.
9. Guettler S., LaRose J., Petsalaki E., Gish G., Scotter A., Pawson T., et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011, 147:1340-1354.
10. Foucault I., Le Bras S., Charvet C., Moon C., Altman A., Deckert M. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 2005, 105:1106-1113.
11. Lietman S.A., Yin L., Levine M.A. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008, 371:644-648.
12. Ueki Y., Lin C.Y., Senoo M., Ebihara T., Agata N., Onji M., et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007, 128:71-83.
13. Kitaura H., Zhou P., Kim H.J., Novack D.V., Ross F.P., Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3418-3427.
14. Burmester G.R., Panaccione R., Gordon K.B., McIlraith M.J., Lacerda A.P.M. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012, http://dx.doi.org/10.1136/annrheumdis-2011-201244.
15. Ruperto N., Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheum 2011, 7:6-7.
16. Reichenberger E.J., Levine M.A., Olsen B.R., Papadaki M.E., Lietman S.A. The role of SH3BP2 in the pathophysiology of cherubism. Orphanet J Rare Dis 2012, 7(Suppl. 1):S5.
17. Novack D.V., Faccio R. Jawing about TNF: new hope for cherubism. Cell 2007, 128:15-17.
18. Southgate J., Sarma U., Townend J.V., Barron J., Flanagan A.M. Study of the cell biology and biochemistry of cherubism. J Clin Pathol 1998, 51:831-837.
19. Neville B., Damm D., Allen C., Bouquout J. Oral and maxillofacial pathology 2009, Sounders, Elsevier, Missouri, USA, pp. 629-630.
20. Pagnini I., Simonini G., Mortilla M., Giani T., Pascoli L., Cimaz R. Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism. Clin Exp Rheumatol 2011, 29:147.
21. Papadaki M.E., Lietman S.A., Levine M.A., Olsen B.R., Kaban L.B., Reichenberger E.J. Cherubism: best clinical practice. Orphanet J Rare Dis 2012, 7(Suppl. 1):S6.